Skip to main content
Terug
Watch Compare

Foghorn Therapeutics Inc.

Datakwaliteit: 100%
FHTX
Nasdaq Manufacturing Chemicals
€ 4,59
▼ € 0,20 (-4,18%)
Marktkapitalisatie: 284,70 M
Prijs
€ 4,85
Marktkapitalisatie
284,70 M
Dagbereik
52-Weeksbereik
Volume
Openen —
50D / 200D Gem.
50D / 200D Gem.

Quick Summary

Belangrijkste Punten

Revenue grew 120,02% annually over 5 years — strong growth
Negative free cash flow of -86,15 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 83,27%
Capital efficient — spends only 0,16% of revenue on capex

Groei

Revenue Growth (5Y)
120,02%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)36,75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-50,87%
Net Margin-240,33%
Op. Margin-279,49%

Veiligheid

Debt / Equity
N/A
Current Ratio2,16
Interest CoverageN/A

Waardering

PE (TTM)
-3,83
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -3,8 -1,5
P/B 1,6
ROE % -53,5
Net Margin % -240,3 -41,5
Rev Growth 5Y % 120,0 1,8
D/E 0,3

Koersdoel Analisten

9 analisten
Buy
Huidig
€ 4,59
+149.3%
Koersdoel
€ 11,44
€ 9,00
€ 12,00
€ 14,00
Vooruitzicht
Forward K/W -5,04
Forward WPA -€ 0,91
Omzet Sch. 44,22 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,91
-€ 1,19 – -€ 0,70
44,22 M 7
FY2026 -€ 1,13
-€ 1,54 – -€ 0,79
33,00 M 5

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,26 -€ 0,37 -42,4%
Q32025 -€ 0,30 -€ 0,25 +16,7%
Q22025 -€ 0,32 -€ 0,28 +12,0%
Q12025 -€ 0,29 -€ 0,30 -3,5%

ETFs Holding This Stock

CNCR CNCR
0,92% weight
BRSIX BRSIX
0,12% weight
GSIOX GSIOX
0,02% weight
GSTOX GSTOX
0,02% weight
GSZPX GSZPX
0,02% weight
GINUX GINUX
0,02% weight
GSROX GSROX
0,02% weight
GSCOX GSCOX
0,02% weight
WSMGX WSMGX
0,01% weight
DTSGX DTSGX
0,01% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y) 36,75% Revenue Growth (3Y) -4,87%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 120,02% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 30,91 M Net Income (TTM) -74,28 M
ROE N/A ROA -34,45%
Gross Margin N/A Operating Margin -279,49%
Net Margin -240,33% Free Cash Flow (TTM) -86,15 M
ROIC -50,87% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,16
Interest Coverage N/A Asset Turnover 0,14
Working Capital 99,03 M Tangible Book Value -89,66 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,83 Forward P/E N/A
P/B Ratio N/A P/S Ratio 9,21
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -30,26%
Market Cap 284,70 M Enterprise Value 195,36 M
Per Share
EPS (Diluted TTM) -1,18 Revenue / Share 0,53
FCF / Share -1,47 OCF / Share -1,47
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,16% FCF Conversion 115,97%
SBC-Adj. FCF -97,33 M Growth Momentum -83,27

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 30,91 M 22,60 M 34,16 M 19,23 M 1,32 M
Net Income -74,28 M -86,62 M -98,43 M -108,88 M -101,32 M
EPS (Diluted) -1,18 -1,58 -2,34 -2,62 -2,73
Gross Profit
Operating Income -86,39 M -102,68 M -107,91 M -117,14 M -100,73 M
EBITDA
R&D Expenses 85,47 M 94,53 M 109,69 M 105,62 M 80,33 M
SG&A Expenses
D&A 3,33 M 3,12 M 3,45 M 3,32 M 3,23 M
Interest Expense 1,91 M
Income Tax 0,0 0,0 4,23 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 198,10 M 283,98 M 285,92 M 404,88 M 519,77 M
Total Liabilities 306,60 M 329,51 M 363,11 M 404,77 M 422,90 M
Shareholders' Equity -108,50 M -45,53 M -77,19 M 112.000,0 96,87 M
Total Debt 0,0
Cash & Equivalents 80,88 M 55,45 M 80,34 M 52,21 M 101,14 M
Current Assets 163,24 M 249,60 M 240,18 M 351,40 M 459,56 M
Current Liabilities 59,74 M 66,99 M 58,44 M 55,21 M 48,69 M